Ribavirin News and Research

RSS
Ribavirin, also known as Copegus, Rebetol, Virazole, or a component of Rebetron, is a type of antiviral medicine called a nucleoside analogue. This medicine blocks the ability of the hepatitis C virus (HCV) to make more copies of itself. Ribavirin is not active against HIV. Ribavirin is used in combination with interferon alfa-2a or -2b or peginterferon alfa-2a or -2b to treat HIV infected patients who are also infected with HCV.
Does Langya virus pose a spillover threat?

Does Langya virus pose a spillover threat?

Study provides insights into understanding the biology of circulating Hepatitis E variants

Study provides insights into understanding the biology of circulating Hepatitis E variants

Scientists introduce SARS-CoV-2 phenotype screening for identifying novel antiviral drugs

Scientists introduce SARS-CoV-2 phenotype screening for identifying novel antiviral drugs

Nitazoxanide drug found to be a potent inhibitor of several human coronaviruses

Nitazoxanide drug found to be a potent inhibitor of several human coronaviruses

What are the biological features, prevention and control strategies against monkeypox?

What are the biological features, prevention and control strategies against monkeypox?

Chemically modified rocaglates have a stronger effect against viral replication

Chemically modified rocaglates have a stronger effect against viral replication

Probenecid shows activity against respiratory syncytial virus

Probenecid shows activity against respiratory syncytial virus

Novel targets to inhibit SARS-CoV-2 variants

Novel targets to inhibit SARS-CoV-2 variants

Trial of early antiviral therapy for COVID-19 shows no significant benefit

Trial of early antiviral therapy for COVID-19 shows no significant benefit

Study explains why Omicron infections are less likely to cause severe disease

Study explains why Omicron infections are less likely to cause severe disease

Study identifies current mechanism of action behind reduced severity of Omicron variant COVID-19 infection

Study identifies current mechanism of action behind reduced severity of Omicron variant COVID-19 infection

Screening FDA-approved compounds shown to possess antiviral or antimicrobial activity for SARS-CoV-2 inhibition

Screening FDA-approved compounds shown to possess antiviral or antimicrobial activity for SARS-CoV-2 inhibition

A survey on computational methods in discovering protein inhibitors of SARS-CoV-2

A survey on computational methods in discovering protein inhibitors of SARS-CoV-2

Potential covalent SARS-CoV-2 spike protein inhibitors

Potential covalent SARS-CoV-2 spike protein inhibitors

Flavonoid-based inhibitors targeting SARS-CoV 3CL protease for the treatment of SARS-CoV-2 infection

Flavonoid-based inhibitors targeting SARS-CoV 3CL protease for the treatment of SARS-CoV-2 infection

Potential compounds targeting SARS-COV-2 main protease (in vivo)

Potential compounds targeting SARS-COV-2 main protease (in vivo)

Researchers review the origins of SARS-CoV-2 and present treatment methods

Researchers review the origins of SARS-CoV-2 and present treatment methods

SARS-CoV-2 NSP14 induces potent inflammation via NF-κB pathways, finds study

SARS-CoV-2 NSP14 induces potent inflammation via NF-κB pathways, finds study

Could graphene oxide nanosheets be an effective SARS-CoV-2 antiviral in PPE?

Could graphene oxide nanosheets be an effective SARS-CoV-2 antiviral in PPE?

Natural products a rich source for novel antiviral compounds

Natural products a rich source for novel antiviral compounds